New Drug Combination for Advanced Bile Duct Cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests two new drugs (becotatug vedotin and pucotenlimab) together for advanced biliary tract cancer—a cancer of the bile ducts or gallbladder. The drugs may help if your cancer has a specific marker (EGFR) and has not responded to earlier treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced biliary tract cancer (bile duct or gallbladder cancer) that has been confirmed with a biopsy
- Your cancer cells show EGFR expression (a protein marker) on a special test
- You have already tried at least one standard cancer treatment that didn't work
- You are generally healthy enough for treatment (ECOG score 0 or 1) and expected to live at least 3 months
- Your blood counts, kidney, and liver function are adequate for the study drugs
- You have not had another cancer in the past 5 years (except skin cancer or early-stage cervical cancer)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug combined with standard chemotherapy as a first treatment for advanced bile duct or gallbladder cancer. It may help your immune system fight the cancer while chemotherapy attacks the tumor directly.
This trial tests a new drug called becotatug vedotin combined with standard chemotherapy for advanced bile duct cancer (a cancer of the tubes that carry bile). The trial is for patients whose cancer has a specific genetic marker called EGFR and whose cancer has already progressed despite previous treatment.
This trial tests a new combination of two drugs—Becotatug Vedotin (a targeted therapy that delivers chemotherapy directly to EGFR-positive cancer cells) and Pucotenlimab (an immunotherapy that helps your immune system fight cancer). It is for people with advanced solid tumors that have not responded to standard treatments.
This trial tests two new cancer-fighting drugs together to treat advanced squamous cell carcinoma (a common type of head and neck cancer) in patients who cannot tolerate or refuse platinum-based chemotherapy. The goal is to see if this combination can shrink or control the cancer.
This study tests whether combining two immunotherapy drugs—pucotenlimab (a PD-1 inhibitor that boosts your immune system) and becotatugvedotin (an antibody-drug that targets EGFR cancer cells)—can shrink advanced cholangiocarcinoma (bile duct or gallbladder cancer). The goal is to see if this combination works better and is safe for patients whose cancer cannot be surgically removed or has spread.
This trial tests a new drug combination for advanced esophageal squamous cell carcinoma that has stopped responding to prior treatment. The goal is to see if the combination can shrink tumors and help patients live longer.
Hear when a new Biliary Tract Cancer (BTC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.